References
1. Ostrom Q, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al.
CBTRUS statistical report: primary brain and central nervous system
tumors diagnosed in the United States in 2007-2011. Neuro-oncology.
2014:iv1-63.
2. Ljubimov V, Ramesh A, Davani S, Danielpour M, Breunig J, Black K.
Neurosurgery at the crossroads of immunology and nanotechnology. New
reality in the COVID-19 pandemic. Advanced drug delivery reviews.
2022;181:114033.
3. Rivoirard R, Vallard A, Langrand-Escure J, Ben Mrad M, Wang G, Guy J,
et al. Thirty years of phase I radiochemotherapy trials: Latest
development. European journal of cancer (Oxford, England : 1990).
2016;58:1-7.
4. Sun G, Rong D, Li Z, Sun G, Wu F, Li X, et al. Role of Small Molecule
Targeted Compounds in Cancer: Progress, Opportunities, and Challenges.
Frontiers in cell and developmental biology. 2021;9:694363.
5. Lin X, DeAngelis LM. Treatment of Brain Metastases. J Clin Oncol.
2015;33(30):3475-84.
6. Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and
blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer.
2020;20(1):26-41.
7. Kirson E, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y,
et al. Disruption of cancer cell replication by alternating electric
fields. Cancer research. 2004;64(9):3288-95.
8. Stupp R, Wong E, Kanner A, Steinberg D, Engelhard H, Heidecke V, et
al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent
glioblastoma: a randomised phase III trial of a novel treatment
modality. European journal of cancer (Oxford, England : 1990).
2012;48(14):2192-202.
9. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et
al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs
Maintenance Temozolomide Alone on Survival in Patients With
Glioblastoma: A Randomized Clinical Trial. JAMA. 2017;318(23):2306-16.
10. Kutuk T, Appel H, Avendano M, Albrecht F, Kaywin P, Ramos S, et al.
Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based
Chemotherapy for Unresectable Malignant Pleural Mesothelioma:
Single-Center, Real-World Data. Cancers. 2022;14(8).
11. Robinson AJ, Jain A, Sherman HG, Hague RJM, Rahman R,
Sanjuan-Alberte P, et al. Toward Hijacking Bioelectricity in Cancer to
Develop New Bioelectronic Medicine. Advanced Therapeutics.
2021;4(3):2000248.
12. Levin M, Stevenson CG. Regulation of Cell Behavior and Tissue
Patterning by Bioelectrical Signals: Challenges and Opportunities for
Biomedical Engineering. Annual Review of Biomedical Engineering.
2012;14(1):295-323.
13. Davies A, Weinberg U, Palti Y. Tumor treating fields: a new frontier
in cancer therapy. Annals of the New York Academy of Sciences.
2013;1291:86-95.
14. Xu S, Luo C, Chen D, Tang L, Chen L, Liu Z. Whole transcriptome and
proteome analyses identify potential targets and mechanisms underlying
tumor treating fields against glioblastoma. Cell Death Dis.
2022;13(8):721.
15. Gutin P, Wong E. Noninvasive application of alternating electric
fields in glioblastoma: a fourth cancer treatment modality. American
Society of Clinical Oncology educational book American Society of
Clinical Oncology Annual Meeting. 2012:126-31.
16. Kline-Smith S, Walczak C. Mitotic spindle assembly and chromosome
segregation: refocusing on microtubule dynamics. Molecular cell.
2004;15(3):317-27.
17. Barreca M, Stathis A, Barraja P, Bertoni F. An overview on
anti-tubulin agents for the treatment of lymphoma patients. Pharmacology
& therapeutics. 2020;211:107552.
18. Voloshin T, Schneiderman R, Volodin A, Shamir R, Kaynan N, Zeevi E,
et al. Tumor Treating Fields (TTFields) Hinder Cancer Cell Motility
through Regulation of Microtubule and Acting Dynamics. Cancers.
2020;12(10).
19. Tooley A, Gilden J, Jacobelli J, Beemiller P, Trimble W, Kinoshita
M, et al. Amoeboid T lymphocytes require the septin cytoskeleton for
cortical integrity and persistent motility. Nature cell biology.
2009;11(1):17-26.
20. Gilden J, Peck S, Chen Y, Krummel M. The septin cytoskeleton
facilitates membrane retraction during motility and blebbing. The
Journal of cell biology. 2012;196(1):103-14.
21. Kirson E, Dbalý V, Tovarys F, Vymazal J, Soustiel J, Itzhaki A, et
al. Alternating electric fields arrest cell proliferation in animal
tumor models and human brain tumors. Proceedings of the National Academy
of Sciences of the United States of America. 2007;104(24):10152-7.
22. Giladi M, Schneiderman R, Voloshin T, Porat Y, Munster M, Blat R, et
al. Mitotic Spindle Disruption by Alternating Electric Fields Leads to
Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells.
Scientific reports. 2015;5:18046.
23. Gera N, Yang A, Holtzman T, Lee S, Wong E, Swanson K. Tumor treating
fields perturb the localization of septins and cause aberrant mitotic
exit. PloS one. 2015;10(5):e0125269.
24. Lee SX, Wong ET, Swanson KD. MITOSIS INTERFERENCE OF CANCER CELLS
DURING ANAPHASE BY ELECTRIC FIELD FROM NOVOTTF-100A. NEURO-ONCOLOGY.
2011;13:13-4.
25. Kim E, Kim Y, Song H, Jeong Y, Lee J, Sung J, et al. Biological
effect of an alternating electric field on cell proliferation and
synergistic antimitotic effect in combination with ionizing radiation.
Oncotarget. 2016;7(38):62267-79.
26. Giladi M, Munster M, Schneiderman R, Voloshin T, Porat Y, Blat R, et
al. Tumor treating fields (TTFields) delay DNA damage repair following
radiation treatment of glioma cells. Radiation oncology (London,
England). 2017;12(1):206.
27. Karanam N, Srinivasan K, Ding L, Sishc B, Saha D, Story M.
Tumor-treating fields elicit a conditional vulnerability to ionizing
radiation via the downregulation of BRCA1 signaling and reduced DNA
double-strand break repair capacity in non-small cell lung cancer cell
lines. Cell death & disease. 2017;8(3):e2711.
28. Zhao W, Steinfeld J, Liang F, Chen X, Maranon D, Jian Ma C, et al.
BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing. Nature.
2017;550(7676):360-5.
29. Kais Z, Rondinelli B, Holmes A, O’Leary C, Kozono D, D’Andrea A, et
al. FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and
Promotes Alternative End-Joining DNA Repair. Cell reports.
2016;15(11):2488-99.
30. Karanam N, Ding L, Aroumougame A, Story M. Tumor treating fields
cause replication stress and interfere with DNA replication fork
maintenance: Implications for cancer therapy. Translational research :
the journal of laboratory and clinical medicine. 2020;217:33-46.
31. Kirson E, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D,
Schneiderman R, et al. Alternating electric fields (TTFields) inhibit
metastatic spread of solid tumors to the lungs. Clinical & experimental
metastasis. 2009;26(7):633-40.
32. Shi P, Tian J, Ulm B, Mallinger J, Khoshbouei H, Deleyrolle L, et
al. Tumor Treating Fields Suppression of Ciliogenesis Enhances
Temozolomide Toxicity. Frontiers in oncology. 2022;12:837589.
33. Kalluri R, Weinberg R. The basics of epithelial-mesenchymal
transition. The Journal of clinical investigation. 2009;119(6):1420-8.
34. Kim E, Song H, Yoo S, Yoon M. Tumor treating fields inhibit
glioblastoma cell migration, invasion and angiogenesis. Oncotarget.
2016;7(40):65125-36.
35. Egeblad M, Werb Z. New functions for the matrix metalloproteinases
in cancer progression. Nature reviews Cancer. 2002;2(3):161-74.
36. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in
cancer. Vascular health and risk management. 2006;2(3):213-9.
37. Inoue T, Nakayama Y, Li Y, Matsumori H, Takahashi H, Kojima H, et
al. SIRT2 knockdown increases basal autophagy and prevents postslippage
death by abnormally prolonging the mitotic arrest that is induced by
microtubule inhibitors. The FEBS journal. 2014;281(11):2623-37.
38. Silginer M, Weller M, Stupp R, Roth P. Biological activity of
tumor-treating fields in preclinical glioma models. Cell death &
disease. 2017;8(4):e2753.
39. Kim E, Jo Y, Sai S, Park M, Kim J, Kim J, et al. Tumor-treating
fields induce autophagy by blocking the Akt2/miR29b axis in glioblastoma
cells. Oncogene. 2019;38(39):6630-46.
40. Holdgaard S, Cianfanelli V, Pupo E, Lambrughi M, Lubas M, Nielsen J,
et al. Selective autophagy maintains centrosome integrity and accurate
mitosis by turnover of centriolar satellites. Nature communications.
2019;10(1):4176.
41. Tsujimoto Y, Shimizu S. Another way to die: autophagic programmed
cell death. Cell Death & Differentiation. 2005;12(2):1528-34.
42. Shteingauz A, Porat Y, Voloshin T, Schneiderman R, Munster M, Zeevi
E, et al. AMPK-dependent autophagy upregulation serves as a survival
mechanism in response to Tumor Treating Fields (TTFields). Cell death &
disease. 2018;9(11):1074.
43. Wong E, Lok E, Gautam S, Swanson K. Dexamethasone exerts profound
immunologic interference on treatment efficacy for recurrent
glioblastoma. British journal of cancer. 2015;113(2):232-41.
44. Voloshin T, Kaynan N, Davidi S, Porat Y, Shteingauz A, Schneiderman
R, et al. Tumor-treating fields (TTFields) induce immunogenic cell death
resulting in enhanced antitumor efficacy when combined with anti-PD-1
therapy. Cancer immunology, immunotherapy : CII. 2020;69(7):1191-204.
45. Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala A, Shen S, et al.
Molecular mechanisms of ATP secretion during immunogenic cell death.
Cell death and differentiation. 2014;21(1):79-91.
46. Park J, Song K, Jung S, Ahn J, Hwang S, Kim J, et al. Tumor-Treating
Fields Induce RAW264.7 Macrophage Activation Via NK-κB/MAPK Signaling
Pathways. Technology in cancer research & treatment.
2019;18:1533033819868225.
47. Chen D, Le S, Hutchinson T, Calinescu A, Sebastian M, Jin D, et al.
Tumor Treating Fields dually activate STING and AIM2 inflammasomes to
induce adjuvant immunity in glioblastoma. The Journal of clinical
investigation. 2022.
48. Aguilar AA, Ho MC, Chang E, Carlson KW, Natarajan A, Marciano T, et
al. Permeabilizing Cell Membranes with Electric Fields. Cancers (Basel).
2021;13(9).
49. Chang E, Patel C, Pohling C, Young C, Song J, Flores T, et al. Tumor
treating fields increases membrane permeability in glioblastoma cells.
Cell death discovery. 2018;4:113.
50. Probst U, Fuhrmann I, Beyer L, Wiggermann P. Electrochemotherapy as
a New Modality in Interventional Oncology: A Review. Technology in
cancer research & treatment. 2018;17:1533033818785329.
51. Neuhaus E, Zirjacks L, Ganser K, Klumpp L, Schüler U, Zips D, et al.
Alternating Electric Fields (TTFields) Activate Ca1.2 Channels in Human
Glioblastoma Cells. Cancers. 2019;11(1).
52. Chinigò G, Castel H, Chever O, Gkika D. TRP Channels in Brain
Tumors. Front Cell Dev Biol. 2021;9:617801.
53. Li X, Yang F, Rubinsky B. A Theoretical Study on the Biophysical
Mechanisms by Which Tumor Treating Fields Affect Tumor Cells During
Mitosis. IEEE transactions on bio-medical engineering.
2020;67(9):2594-602.
54. Kessler AF, Salvador E, Domrose D, Burek M, Schaeffer C, Brami CT,
et al. Blood Brain Barrier (BBB) Integrity Is Affected By Tumor Treating
Fields (TTFields) in Vitro and In Vivo. International Journal of
Radiation Oncology Biology Physics. 2019;105(1):S162-S3.
55. Ceresoli G, Aerts J, Dziadziuszko R, Ramlau R, Cedres S, van
Meerbeeck J, et al. Tumour Treating Fields in combination with
pemetrexed and cisplatin or carboplatin as first-line treatment for
unresectable malignant pleural mesothelioma (STELLAR): a multicentre,
single-arm phase 2 trial. The Lancet Oncology. 2019;20(12):1702-9.
56. Giladi M, Schneiderman R, Porat Y, Munster M, Itzhaki A,
Mordechovich D, et al. Mitotic disruption and reduced clonogenicity of
pancreatic cancer cells in vitro and in vivo by tumor treating fields.
Pancreatology : official journal of the International Association of
Pancreatology (IAP) [et al]. 2014;14(1):54-63.
57. Akbarnejad Z, Eskandary H, Dini L, Vergallo C, Nematollahi-Mahani S,
Farsinejad A, et al. Cytotoxicity of temozolomide on human glioblastoma
cells is enhanced by the concomitant exposure to an extremely
low-frequency electromagnetic field (100Hz, 100G). Biomedicine &
pharmacotherapy = Biomedecine & pharmacotherapie. 2017;92:254-64.
58. Branter J, Estevez-Cebrero M, Diksin M, Griffin M, Castellanos-Uribe
M, May S, et al. Genome-Wide Expression and Anti-Proliferative Effects
of Electric Field Therapy on Pediatric and Adult Brain Tumors.
International journal of molecular sciences. 2022;23(4).
59. Kirson ED, Wasserman Y, Izhaki A, Mordechovich D, Gurvich Z, Dbaly
V, et al. Modeling tumor growth kinetics and its implications for
TTFields treatment planning. Neuro-Oncology. 2010:48-.
60. Norden A, Young G, Setayesh K, Muzikansky A, Klufas R, Ross G, et
al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and
patterns of recurrence. Neurology. 2008;70(10):779-87.
61. Iwamoto F, Abrey L, Beal K, Gutin P, Rosenblum M, Reuter V, et al.
Patterns of relapse and prognosis after bevacizumab failure in recurrent
glioblastoma. Neurology. 2009;73(15):1200-6.
62. Rosen J, Blau T, Grau S, Barbe M, Fink G, Galldiks N. Extracranial
Metastases of a Cerebral Glioblastoma: A Case Report and Review of the
Literature. Case reports in oncology. 2018;11(2):591-600.
63. Korshoej A, Lukacova S, Lassen-Ramshad Y, Rahbek C, Severinsen K,
Guldberg T, et al. OptimalTTF-1: Enhancing tumor treating fields therapy
with skull remodeling surgery. A clinical phase I trial in adult
recurrent glioblastoma. Neuro-oncology advances. 2020;2(1):vdaa121.
64. Mikic N, Poulsen F, Kristoffersen K, Laursen R, Guldberg T,
Skjøth-Rasmussen J, et al. Study protocol for OptimalTTF-2: enhancing
Tumor Treating Fields with skull remodeling surgery for first recurrence
glioblastoma: a phase 2, multi-center, randomized, prospective,
interventional trial. BMC cancer. 2021;21(1):1010.
65. Fisher J, Adamson D. Current FDA-Approved Therapies for High-Grade
Malignant Gliomas. Biomedicines. 2021;9(3).
66. Lazaridis L, Schäfer N, Teuber-Hanselmann S, Blau T, Schmidt T,
Oster C, et al. Tumour Treating Fields (TTFields) in combination with
lomustine and temozolomide in patients with newly diagnosed
glioblastoma. Journal of cancer research and clinical oncology.
2020;146(3):787-92.
67. Bokstein F, Blumenthal D, Limon D, Harosh C, Ram Z, Grossman R.
Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for
Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility
Study. Frontiers in oncology. 2020;10:411.
68. Miller R, Song A, Ali A, Niazi M, Bar-Ad V, Martinez N, et al.
Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating
Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma. Frontiers
in oncology. 2022;12:896246.
69. Lin Y, Chen B. Case report: tumor-treating fields prolongs
IDH-mutant anaplastic astrocytoma progression-free survival and
pathological evolution to glioblastoma. Annals of translational
medicine. 2021;9(24):1804.
70. Majores M, von Lehe M, Fassunke J, Schramm J, Becker AJ, Simon M.
Tumor recurrence and malignant progression of gangliogliomas. Cancer.
2008;113(12):3355-63.
71. Meletath S, Pavlick D, Brennan T, Hamilton R, Chmielecki J, Elvin J,
et al. Personalized Treatment for a Patient With a BRAF V600E Mutation
Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade
Glioma Arising From Ganglioglioma. Journal of the National Comprehensive
Cancer Network : JNCCN. 2016;14(11):1345-50.
72. Achrol A, Rennert R, Anders C, Soffietti R, Ahluwalia M, Nayak L, et
al. Brain metastases. Nature reviews Disease primers. 2019;5(1):5.
73. Kirschenbaum D, Amit I. Brain metastases: Not all tumors are created
equal. Neuron. 2022;110(7):1097-9.
74. Mehta M, Gondi V, Ahluwalia M, Brown P. Radiosurgery followed by
tumour treating fields (TTFields) for brain metastases (1-10) from NSCLC
in the phase III METIS trial. Annals of Oncology. 2019;30.
75. Wu H, Yang L, Liu H, Zhou D, Chen D, Zheng X, et al. Exploring the
efficacy of tumor electric field therapy against glioblastoma: An in
vivo and in vitro study. CNS neuroscience & therapeutics.
2021;27(12):1587-604.
76. Elzinga G, Wong E. Resolution of cystic enhancement to add-on tumor
treating electric fields for recurrent glioblastoma after incomplete
response to bevacizumab. Case reports in neurology. 2014;6(1):109-15.
77. Lu G, Rao M, Zhu P, Liang B, El-Nazer R, Fonkem E, et al.
Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus
Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study.
Frontiers in neurology. 2019;10:42.
78. Den R, Kamrava M, Sheng Z, Werner-Wasik M, Dougherty E, Marinucchi
M, et al. A phase I study of the combination of sorafenib with
temozolomide and radiation therapy for the treatment of primary and
recurrent high-grade gliomas. International journal of radiation
oncology, biology, physics. 2013;85(2):321-8.
79. Jo Y, Kim E, Sai S, Kim J, Cho J, Kim H, et al. Functional
Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer
for Glioblastoma Therapy. International journal of molecular sciences.
2018;19(11).
80. Kessler A, Frömbling G, Gross F, Hahn M, Dzokou W, Ernestus R, et
al. Effects of tumor treating fields (TTFields) on glioblastoma cells
are augmented by mitotic checkpoint inhibition. Cell death discovery.
2018;4:12.
81. Jo Y, Han Y, Lee E, Seo J, Oh G, Sung H, et al. The combination of
tumor treating fields and hyperthermia has synergistic therapeutic
effects in glioblastoma cells by downregulating STAT3. American journal
of cancer research. 2022;12(3):1423-32.
82. Lee J, Grabowski M, Lathia J. Tumor Treating Fields: killing two
birds with one stone. The Journal of clinical investigation.
2022;132(8).
83. Wen P, Macdonald D, Reardon D, Cloughesy T, Sorensen A, Galanis E,
et al. Updated response assessment criteria for high-grade gliomas:
response assessment in neuro-oncology working group. Journal of clinical
oncology : official journal of the American Society of Clinical
Oncology. 2010;28(11):1963-72.
84. Jackson E, Barboriak D, Bidaut L, Meyer C. Magnetic resonance
assessment of response to therapy: tumor change measurement, truth data
and error sources. Translational oncology. 2009;2(4):211-5.
85. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent M. Clinical
features, mechanisms, and management of pseudoprogression in malignant
gliomas. The Lancet Oncology. 2008;9(5):453-61.
86. Mohan S, Chawla S, Wang S, Verma G, Skolnik A, Brem S, et al.
Assessment of early response to tumor-treating fields in newly diagnosed
glioblastoma using physiologic and metabolic MRI: initial experience.
CNS oncology. 2016;5(3):137-44.
87. Tian M, He X, Jin C, He X, Wu S, Zhou R, et al. Transpathology:
molecular imaging-based pathology. Eur J Nucl Med Mol Imaging.
2021;48(8):2338-50.
88. Werner J, Lohmann P, Fink G, Langen K, Galldiks N. Current Landscape
and Emerging Fields of PET Imaging in Patients with Brain Tumors.
Molecules (Basel, Switzerland). 2020;25(6).
89. Langen K, Watts C. Neuro-oncology: Amino acid PET for brain tumours
- ready for the clinic? Nature reviews Neurology. 2016;12(7):375-6.
90. Singhal T, Narayanan T, Jain V, Mukherjee J, Mantil J.
11C-L-methionine positron emission tomography in the clinical management
of cerebral gliomas. Molecular imaging and biology. 2008;10(1):1-18.
91. Ceccon G, Lazaridis L, Stoffels G, Rapp M, Weber M, Blau T, et al.
Use of FET PET in glioblastoma patients undergoing neurooncological
treatment including tumour-treating fields: initial experience. European
journal of nuclear medicine and molecular imaging. 2018;45(9):1626-35.
92. Bosnyák E, Barger G, Michelhaugh S, Robinette N, Amit-Yousif A,
Mittal S, et al. Amino Acid PET Imaging of the Early Metabolic Response
During Tumor-Treating Fields (TTFields) Therapy in Recurrent
Glioblastoma. Clinical nuclear medicine. 2018;43(3):176-9.
93. Witney T, James M, Shen B, Chang E, Pohling C, Arksey N, et al. PET
imaging of tumor glycolysis downstream of hexokinase through noninvasive
measurement of pyruvate kinase M2. Science translational medicine.
2015;7(310):310ra169.
94. Christofk H, Vander Heiden M, Harris M, Ramanathan A, Gerszten R,
Wei R, et al. The M2 splice isoform of pyruvate kinase is important for
cancer metabolism and tumour growth. Nature. 2008;452(7184):230-3.
95. Patel C, Beinat C, Xie Y, Chang E, Gambhir S. Tumor treating fields
(TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by
[F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2)
expression. Neoplasia (New York, NY). 2021;23(1):58-67.
96. DeBerardinis R, Chandel N. We need to talk about the Warburg effect.
Nature metabolism. 2020;2(2):127-9.
97. Xu K, Yin N, Peng M, Stamatiades E, Chhangawala S, Shyu A, et al.
Glycolytic ATP fuels phosphoinositide 3-kinase signaling to support
effector T helper 17 cell responses. Immunity. 2021;54(5):976-87.e7.
98. Taphoorn M, Dirven L, Kanner A, Lavy-Shahaf G, Weinberg U,
Taillibert S, et al. Influence of Treatment With Tumor-Treating Fields
on Health-Related Quality of Life of Patients With Newly Diagnosed
Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA
oncology. 2018;4(4):495-504.
99. Lacouture M, Davis M, Elzinga G, Butowski N, Tran D, Villano J, et
al. Characterization and management of dermatologic adverse events with
the NovoTTF-100A System, a novel anti-mitotic electric field device for
the treatment of recurrent glioblastoma. Seminars in oncology.
2014:S1-14.
100. Toms S, Kim C, Nicholas G, Ram Z. Increased compliance with tumor
treating fields therapy is prognostic for improved survival in the
treatment of glioblastoma: a subgroup analysis of the EF-14 phase III
trial. Journal of neuro-oncology. 2019;141(2):467-73.
101. Gatson N, Barnholtz-Sloan J, Drappatz J, Henriksson R, Hottinger A,
Hinoul P, et al. Tumor Treating Fields for Glioblastoma Therapy During
the COVID-19 Pandemic. Frontiers in oncology. 2021;11:679702.
102. Green A, Mulcahy Levy J, Vibhakar R, Hemenway M, Madden J, Foreman
N, et al. Tumor treating fields in pediatric high-grade glioma. Child’s
nervous system : ChNS : official journal of the International Society
for Pediatric Neurosurgery. 2017;33(7):1043-5.
103. Wenger C, Miranda P, Salvador R, Thielscher A, Bomzon Z, Giladi M,
et al. A Review on Tumor-Treating Fields (TTFields): Clinical
Implications Inferred From Computational Modeling. IEEE reviews in
biomedical engineering. 2018;11:195-207.
104. Mehta M, Wen P, Nishikawa R, Reardon D, Peters K. Critical review
of the addition of tumor treating fields (TTFields) to the existing
standard of care for newly diagnosed glioblastoma patients. Critical
reviews in oncology/hematology. 2017;111:60-5.
105. Vergote I, von Moos R, Manso L, Van Nieuwenhuysen E, Concin N,
Sessa C. Tumor Treating Fields in combination with paclitaxel in
recurrent ovarian carcinoma: Results of the INNOVATE pilot study.
Gynecologic oncology. 2018;150(3):471-7.
106. Wick W. TTFields: where does all the skepticism come from?
Neuro-oncology. 2016;18(3):303-5.
107. Burri S, Gondi V, Brown P, Mehta M. The Evolving Role of Tumor
Treating Fields in Managing Glioblastoma: Guide for Oncologists.
American journal of clinical oncology. 2018;41(2):191-6.
108. Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J,
Armoiry X. The cost-effectiveness of tumor-treating fields therapy in
patients with newly diagnosed glioblastoma. Neuro-oncology.
2016;18(8):1129-36.
109. Haj A, Doenitz C, Hohenberger C, Brawanski A, Proescholdt MA.
P01.144 TTFields for newly diagnosed Glioblastoma: Impact of
consultation strategy. (1522-8517 (Print)).
110. Salzberg M, Kirson E, Palti Y, Rochlitz C. A pilot study with very
low-intensity, intermediate-frequency electric fields in patients with
locally advanced and/or metastatic solid tumors. Onkologie.
2008;31(7):362-5.